{
    "id": 16814,
    "fullName": "ETV1 fusion",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ETV1 fusion indicates a fusion of the ETV1 gene, but the fusion partner is unknown.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 2115,
        "geneSymbol": "ETV1",
        "terms": [
            "ETV1",
            "ER81"
        ]
    },
    "variant": "fusion",
    "createDate": "01/18/2016",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5403,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) decreased tumor volume in both cell line and patient-derived xenograft models of prostate cancer harboring an ETV1 fusion (PMID: 21575865).",
            "molecularProfile": {
                "id": 17090,
                "profileName": "ETV1 fusion"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3390,
                    "pubMedId": 21575865,
                    "title": "Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21575865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20793,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (NCI 9012) trial, the presence of ERG rearrangement or ETV1 fusion did not predict PSA response rate, measurable disease response rate, or median progression-free survival in patients with metastatic castration-resistant prostate cancer treated with Veliparib (ABT-888), Zytiga (abiraterone), and Prednisone combination therapy (PMID: 29261439; NCT01576172).",
            "molecularProfile": {
                "id": 17090,
                "profileName": "ETV1 fusion"
            },
            "therapy": {
                "id": 5913,
                "therapyName": "Abiraterone + Prednisone + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not predictive",
            "references": [
                {
                    "id": 18044,
                    "pubMedId": 29261439,
                    "title": "Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29261439"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9696,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mivebresib (ABBV-075) inhibited AR and ETS-family target gene expression in a hormone-dependent prostate cancer cell line harboring AR T878A and an ETV1 fusion in culture, and inhibited tumor growth in xenograft models (PMID: 27707886).",
            "molecularProfile": {
                "id": 26984,
                "profileName": "ETV1 fusion AR T878A"
            },
            "therapy": {
                "id": 4028,
                "therapyName": "Mivebresib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7485,
                    "pubMedId": 27707886,
                    "title": "Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27707886"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9701,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mivebresib (ABBV-075) inhibited ETS-family target gene expression and proliferation of an Xtandi (enzalutamide)-resistant prostate cancer cell line harboring AR T878A and AR L702H as well as an ETV1 fusion in culture (PMID: 27707886).",
            "molecularProfile": {
                "id": 26987,
                "profileName": "ETV1 fusion AR L702H AR T878A"
            },
            "therapy": {
                "id": 4028,
                "therapyName": "Mivebresib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7485,
                    "pubMedId": 27707886,
                    "title": "Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27707886"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17090,
            "profileName": "ETV1 fusion",
            "profileTreatmentApproaches": [
                {
                    "id": 7415,
                    "name": "YK-4-279",
                    "profileName": "ETV1 fusion"
                }
            ]
        },
        {
            "id": 26984,
            "profileName": "ETV1 fusion AR T878A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26987,
            "profileName": "ETV1 fusion AR L702H AR T878A",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}